Last reviewed · How we verify
Pulmicort Turbuhaler
Pulmicort (budesonide) is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in lung tissue.
Pulmicort (budesonide) is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in lung tissue. Used for Asthma (maintenance and reliever therapy), Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Pulmicort Turbuhaler |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Budesonide exerts its anti-inflammatory effects by activating glucocorticoid receptors in the cytoplasm of airway cells, which translocate to the nucleus and modulate gene expression. This leads to decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and reduced recruitment of inflammatory cells to the airways. The Turbuhaler is a dry powder inhaler formulation that delivers the drug directly to the lungs for local action.
Approved indications
- Asthma (maintenance and reliever therapy)
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Nervousness
- Palpitations
- Muscle cramps
- Oral candidiasis
Key clinical trials
- Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis (PHASE2)
- Efficacy of Low-Dose Topical Steroids in Maintaining Remission of Eosinophilic Esophagitis in Children
- A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects (PHASE1)
- A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS) (PHASE3)
- The Budesonide in Babies (BiB) Trial (PHASE3)
- Pulmicort Respules on Relapse Rates After Treatment in the ED (PHASE4)
- Anti-Inflammatory Reliever South Africa (PHASE3)
- ARrest RESpiraTory Failure From PNEUMONIA (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pulmicort Turbuhaler CI brief — competitive landscape report
- Pulmicort Turbuhaler updates RSS · CI watch RSS
- AstraZeneca portfolio CI